Plus Therapeutics, Inc. has been granted a 180-day extension by Nasdaq to meet the $1.00 minimum bid price requirement.
The extension provides the Company with additional time to work towards compliance without an immediate need for a reverse stock split.
The Company must achieve a minimum closing bid price of $1.00 per share for 10 consecutive business days by May 11, 2026, to regain compliance.
Extension Granted
The Nasdaq Listing Qualifications Department granted Plus Therapeutics, Inc. a 180-day extension to regain compliance with the minimum bid price requirement.
Compliance Deadline
The Company has until May 11, 2026, to meet the $1.00 minimum bid price requirement to avoid delisting.
No Immediate Impact
The extension notice does not affect the current listing status of Plus Therapeutics on the Nasdaq Capital Market.
- The extension provides Plus Therapeutics with a strategic opportunity to focus on improving its bid price without immediate market pressure.
- Maintaining compliance with listing requirements is crucial for the Company's continued presence on the Nasdaq Capital Market.
The extension granted to Plus Therapeutics offers a lifeline to work towards regaining compliance with Nasdaq's minimum bid price requirement, highlighting the Company's dedication to meeting regulatory standards.